Elanco Animal Health (NYSE:ELAN) Price Target Raised to $23.00 at Stifel Nicolaus

Elanco Animal Health (NYSE:ELAN) had its target price raised by Stifel Nicolaus from $18.00 to $23.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research firms also recently issued reports on ELAN. Wall Street Zen raised Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. Zacks Research cut Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. William Blair raised Elanco Animal Health from a “market perform” rating to an “outperform” rating in a report on Thursday, June 26th. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Finally, Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective on the stock in a report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average price target of $18.33.

Elanco Animal Health Trading Up 1.2%

Shares of NYSE:ELAN opened at $18.76 on Wednesday. The business’s 50-day moving average is $17.01 and its 200 day moving average is $13.61. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $19.35. The firm has a market capitalization of $9.32 billion, a P/E ratio of 21.82, a P/E/G ratio of 3.44 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Trading of Elanco Animal Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MTM Investment Management LLC raised its position in shares of Elanco Animal Health by 5.5% in the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after acquiring an additional 800 shares during the period. HighTower Advisors LLC boosted its position in Elanco Animal Health by 7.0% during the first quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock worth $131,000 after purchasing an additional 810 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Elanco Animal Health by 8.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock worth $169,000 after purchasing an additional 944 shares in the last quarter. M&T Bank Corp grew its holdings in Elanco Animal Health by 4.0% in the second quarter. M&T Bank Corp now owns 25,029 shares of the company’s stock valued at $358,000 after purchasing an additional 971 shares during the period. Finally, ProShare Advisors LLC increased its position in shares of Elanco Animal Health by 8.7% in the second quarter. ProShare Advisors LLC now owns 12,439 shares of the company’s stock valued at $178,000 after buying an additional 999 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.